Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Minneapolis, MN
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Omaha, NE
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Henderson, NV
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Lake Success, NY
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Latham, NY
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Latham, NY
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Eugene, OR
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Eugene, OR
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Portland, OR
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Philadelphia, PA
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Nashville, TN
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Dallas, TX
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Fort Worth, TX
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Plano, TX
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
San Antonio, TX
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Webster, TX
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Low Moor, VA
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Low Moor, VA
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Everett, WA
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Everett, WA
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Seattle, WA
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Milwaukee, WI
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Investigational Site Number 056010
mi
from
Aalst,
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Investigational Site Number 056010
mi
from
Aalst,
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Weslaco, TX
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Weslaco, TX
Click here to add this to my saved trials
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated:  8/24/2017
Clinical Research Facility
mi
from
Tucson, AZ
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Status: Enrolling
Updated: 8/24/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Status: Enrolling
Updated:  8/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Status: Enrolling
Updated: 8/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy
Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy: a Pilot Study
Status: Enrolling
Updated:  8/24/2017
NYU Langone Medical Center
mi
from
New York, NY
Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy
Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy: a Pilot Study
Status: Enrolling
Updated: 8/24/2017
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions
Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions
Status: Enrolling
Updated:  8/28/2017
The Mayo Clinic
mi
from
Rochester, MN
Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions
Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions
Status: Enrolling
Updated: 8/28/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of SU11248 (Sutent) in Combination With Metronomic Dosing of Cyclophosphamide and Methotrexate in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  8/30/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
Phase I/II Study of SU11248 (Sutent) in Combination With Metronomic Dosing of Cyclophosphamide and Methotrexate in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 8/30/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Vitamin D in Postmenopausal Women at High Risk for Breast Cancer
Effects of High-Dose Vitamin D on Circulating Vitamin D Levels and Breast Density in Postmenopausal Women at High Risk for Breast Cancer Development
Status: Enrolling
Updated:  8/30/2017
Columbia University
mi
from
New York, NY
Vitamin D in Postmenopausal Women at High Risk for Breast Cancer
Effects of High-Dose Vitamin D on Circulating Vitamin D Levels and Breast Density in Postmenopausal Women at High Risk for Breast Cancer Development
Status: Enrolling
Updated: 8/30/2017
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer
Pilot Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated:  8/30/2017
Columbia University Medical Center-Herbert Irving Cancer Center
mi
from
New York, NY
Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer
Pilot Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
Status: Enrolling
Updated: 8/30/2017
Columbia University Medical Center-Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients
FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients
Status: Enrolling
Updated:  8/30/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients
FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients
Status: Enrolling
Updated: 8/30/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery
A Phase II Study of Letrozole in Combination With Bevacizumab in Patients With Estrogen Receptor- and/or Progesterone Receptor-Positive Unresectable Locally Advanced and/or Metastatic (Stage IV) Breast Cancer
Status: Enrolling
Updated:  8/30/2017
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery
A Phase II Study of Letrozole in Combination With Bevacizumab in Patients With Estrogen Receptor- and/or Progesterone Receptor-Positive Unresectable Locally Advanced and/or Metastatic (Stage IV) Breast Cancer
Status: Enrolling
Updated: 8/30/2017
UCSF Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery
A Phase II Study of Letrozole in Combination With Bevacizumab in Patients With Estrogen Receptor- and/or Progesterone Receptor-Positive Unresectable Locally Advanced and/or Metastatic (Stage IV) Breast Cancer
Status: Enrolling
Updated:  8/30/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery
A Phase II Study of Letrozole in Combination With Bevacizumab in Patients With Estrogen Receptor- and/or Progesterone Receptor-Positive Unresectable Locally Advanced and/or Metastatic (Stage IV) Breast Cancer
Status: Enrolling
Updated: 8/30/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery
Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin + Daily Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Abraxane™ for 12 Weeks With Concurrent Herceptin for Subjects With HER-2/Neu Positive Disease, Phase II
Status: Enrolling
Updated:  8/30/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery
Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin + Daily Oral Cytoxan With Continuous G-CSF Support for 12 Weeks Followed by Weekly Abraxane™ for 12 Weeks With Concurrent Herceptin for Subjects With HER-2/Neu Positive Disease, Phase II
Status: Enrolling
Updated: 8/30/2017
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
A Pilot Trial to Assess the Impact of Acupuncture on Post-mastectomy Pain, Nausea, Anxiety and Ability to Cope
A Pilot Randomized Controlled Trial to Assess the Impact of Acupuncture on Post-mastectomy Pain, Nausea, Anxiety and Ability to Cope.
Status: Enrolling
Updated:  9/6/2017
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
A Pilot Trial to Assess the Impact of Acupuncture on Post-mastectomy Pain, Nausea, Anxiety and Ability to Cope
A Pilot Randomized Controlled Trial to Assess the Impact of Acupuncture on Post-mastectomy Pain, Nausea, Anxiety and Ability to Cope.
Status: Enrolling
Updated: 9/6/2017
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Status: Enrolling
Updated:  9/8/2017
NYU Clinical Cancer Center
mi
from
New York, NY
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Status: Enrolling
Updated: 9/8/2017
NYU Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Status: Enrolling
Updated:  9/8/2017
NYU Rusk Institute of Rehabilitation Medicine
mi
from
New York, NY
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Status: Enrolling
Updated: 9/8/2017
NYU Rusk Institute of Rehabilitation Medicine
mi
from
New York, NY
Click here to add this to my saved trials
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Status: Enrolling
Updated:  9/8/2017
Tisch Hospital
mi
from
New York, NY
LLLT Combined With CDT in Breast Cancer-Related Lymphedema
The Effectiveness of Low Level Laser Therapy (LLLT)Combined With Complex Decongestive Therapy (CDT) in the Treatment of Breast Cancer-Related Lymphedema: A Double-Blind, Randomized, Placebo-Controlled Study
Status: Enrolling
Updated: 9/8/2017
Tisch Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Methylselenocysteine Effects on Circadian Rhythm
Chemoprevention of Breast and Prostate Cancers in Shift Workers by Dietary Methylselenocysteine: Effects on Circadian Rhythm and Estrogen Receptor-B Cycling
Status: Enrolling
Updated:  9/11/2017
Environmental and Occupational Health Sciences Institute
mi
from
Piscataway, NJ
Methylselenocysteine Effects on Circadian Rhythm
Chemoprevention of Breast and Prostate Cancers in Shift Workers by Dietary Methylselenocysteine: Effects on Circadian Rhythm and Estrogen Receptor-B Cycling
Status: Enrolling
Updated: 9/11/2017
Environmental and Occupational Health Sciences Institute
mi
from
Piscataway, NJ
Click here to add this to my saved trials
Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
Flaxseed vs. Aromatase Inhibitors: Breast Tumor Characteristics and Prognosis
Status: Enrolling
Updated:  9/11/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
Flaxseed vs. Aromatase Inhibitors: Breast Tumor Characteristics and Prognosis
Status: Enrolling
Updated: 9/11/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women With Breast Cancer Following Initiation of Aromatase Inhibitor Therapy
Status: Enrolling
Updated:  9/12/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women With Breast Cancer Following Initiation of Aromatase Inhibitor Therapy
Status: Enrolling
Updated: 9/12/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  9/20/2017
University of Wisconsin
mi
from
Madison, WI
A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 9/20/2017
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of Arizona Cancer Center
mi
from
Tucson, AZ
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of California - LAC Medical Center
mi
from
Los Angeles, CA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of California - LAC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of Southern California, Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of Southern California, Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
UC Irvine Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
UC Irvine Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
GRU Cancer Center - Georgia Regents University
mi
from
Augusta, GA
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
GRU Cancer Center - Georgia Regents University
mi
from
Augusta, GA
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
National Cancer Institute
mi
from
Bethesda, MD
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
National Cancer Institute
mi
from
Bethesda, MD
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
Cancer and Hematology Centers of Western Michigan
mi
from
Grand Rapids, MI
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
Cancer and Hematology Centers of Western Michigan
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
The Long Islan Brain Tumor Center at Neurological Surgery P.C.
mi
from
Commack, NY
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
The Long Islan Brain Tumor Center at Neurological Surgery P.C.
mi
from
Commack, NY
Click here to add this to my saved trials
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated:  9/20/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Status: Enrolling
Updated: 9/20/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials